Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05396781 · ClinicalTrials.gov registry record · Phase 2
Acceptability and Performance of a Mobile Optical Biopsy Technology for Gastrointestinal Cancer Screening
A Phase 2 study, sponsored by Anandasabapathy, Sharmila, M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT05396781 is a Phase 2 study that has completed, run by Anandasabapathy, Sharmila, M.D.. The registered enrollment target is 41 participants.
The verdict
NCT05396781, a Phase 2 study, has completed, sponsored by Anandasabapathy, Sharmila, M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The investigators have a current trial in China and the US which provides significant support for the safety, cost-effectiveness, accuracy and efficiency of a high resolution microendoscope (HRME)-guided approach in the hands of experienced clinicians. To improve functionality, portability and broader use of this device by non-experts, the investigators recently developed a prototype marHRME platform with an automated, augmented reality (AR)-interpretation that provides an overlaid endoscopic + micro-endoscopic view, facilitating diagnosis and biopsy targeting.
Interventions
- DRUG Proflavine
- DEVICE Mobile, Augmented High Resolution Microendoscope
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2022-01-13 |
| Est. Completion | 2022-01-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05396781
The ClinicalTrials.gov registry entry for NCT05396781 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anandasabapathy, Sharmila, M.D., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Proflavine is the first listed.
NCT05396781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05396781 about?
NCT05396781 is a clinical study titled "Acceptability and Performance of a Mobile Optical Biopsy Technology for Gastrointestinal Cancer Screening". The investigators have a current trial in China and the US which provides significant support for the safety, cost-effectiveness, accuracy and efficiency of a high resolution microendoscope (HRME)-guided approach in the hands of experienced clinicians. To improve functionality, portability and broad...
What is the current status of trial NCT05396781?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2022-01-13. Estimated completion is 2022-01-20.
What interventions are being tested in trial NCT05396781?
The interventions under investigation include: Proflavine (DRUG), Mobile, Augmented High Resolution Microendoscope (DEVICE).
Who is sponsoring clinical trial NCT05396781?
This trial is sponsored by Anandasabapathy, Sharmila, M.D., which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.